Blog

Defendant Solvency and the Business Case for MDL 3140
March 11, 2026 by Mohr Marketing MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to… Continue reading Defendant Solvency and the Business Case for MDL 3140
Medical Integrity the Only Path to Defensible Depo-Provera Docket
March 10, 2026 by Mohr Marketing The Precision Mandate: Why Medical Integrity is the Only Path to a Defensible Depo-Provera Docket The pharmaceutical liability landscape shifted significantly with the consolidation of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the sheer scale of the potential plaintiff pool—estimated at 74 million users—is a headline-grabber, the true story of this litigation lies… Continue reading Medical Integrity the Only Path to Defensible Depo-Provera Docket
Scalable MVA Case Acquisition: AI-Driven Police Report Strategies
March 2, 2026 by Mohr Marketing Mohr Marketing Redefines Motor Vehicle Accident Case Acquisition with Exclusive Police Report Data Strategy and AI-Driven DPPA Compliance ALLENTOWN, PA — Mohr Marketing, LLC, a leader in B2B client acquisition for legal professionals, officially announces the launch of its groundbreaking Police Report-Backed MVA Case Acquisition Program. This innovative strategy leverages direct access to official law… Continue reading Scalable MVA Case Acquisition: AI-Driven Police Report Strategies
The Gold Standard in MVA Case Acquisition
February 28, 2026 by Mohr Marketing Direct-from-Source Data | Law Enforcement Partnership | Nationwide Scale In a market saturated with unverified digital leads, Mohr Marketing, LLC provides the one thing that truly matters: Certainty. Through our partnership with a major law enforcement-owned agency, we deliver high-value MVA cases backed by official police reports. The Three Pillars of Our Lead Integrity 1.… Continue reading The Gold Standard in MVA Case Acquisition
The GLP-1 Litigation Landscape has Shifted
February 28, 2026 by Mohr Marketing Mohr Marketing Deploys AI WebTracker® to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the deployment of enhanced precision-targeting technologies to assist law firms in securing high-value claims. With federal case counts nearing 3,200 actions in MDL 3094 and… Continue reading The GLP-1 Litigation Landscape has Shifted
Why Police-Report Data is the Future of MVA Lead Generation
February 27, 2026 by Mohr Marketing The Death of the “Internet Lead”: Why Police-Report-Based Data is the Future of MVA Law For a decade, digital marketing for personal injury firms was a volume game. If you bought enough clicks, you’d eventually find a case. But in 2026, that model is broken. Between AI-generated lead fraud and rising “cost-per-click” rates, firms are… Continue reading Why Police-Report Data is the Future of MVA Lead Generation
The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
February 26, 2026 by Mohr Marketing The Compliance Shield: Why Diagnostic Proof is the New Gold Standard To qualify for a claim in the 2026 Ozempic (Semaglutide) MDL, the court now requires specific medical evidence to distinguish drug-induced injuries from pre-existing conditions. Use this checklist to determine if a potential claimant meets the February 2026 court standards for Gastroparesis or NAION.… Continue reading The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
The 2026 Ozempic Litigation Pivot: From Symptoms to Scintigraphy
February 24, 2026 by Mohr Marketing Ozempic Litigation Update 2026: The Critical Shift to Objective Proof As of February 2026, the Ozempic litigation (MDL 3094 and the newly formed NAION-specific MDL 3163) has shifted from general “failure to warn” claims to a rigorous, evidence-based phase. The court now requires high-level diagnostic proof to separate drug-induced injuries from pre-existing conditions like diabetic… Continue reading The 2026 Ozempic Litigation Pivot: From Symptoms to Scintigraphy
Compliant GLP-1 Mass Tort Case Generation: AI-Verified & Signed
February 23, 2026 by Mohr Marketing The Compliance Choice: Audit-Proof Your GLP-1 Inventory: The “Digital Birth Certificate” Solution The Ozempic (semaglutide) multidistrict litigation (MDL 3094) has entered a high-stakes phase in 2026, with a sharpened focus on medical verification and emerging evidence linking the drug to permanent injuries. Medical Evidence: NAION and Gastroparesis New clinical data is driving the current litigation… Continue reading Compliant GLP-1 Mass Tort Case Generation: AI-Verified & Signed
GLP-1 Signed Cases: High-Quality Mass Tort Case Acquisition
February 22, 2026 by Mohr Marketing Beyond Leads: Why “Signed Cases” are the Future of GLP-1 Mass Tort Litigation The GLP-1 litigation landscape, encompassing blockbuster drugs like Ozempic, Wegovy, and Mounjaro, is experiencing an unprecedented surge in activity. For mass tort firms, the immediate appeal of a vast claimant pool is undeniable. Yet, as the MDL progresses towards critical bellwether selections… Continue reading GLP-1 Signed Cases: High-Quality Mass Tort Case Acquisition
Secret Link